

to ensure the safety of humankind

Gerard López Lacalle

Grau Microbiologia Universitat Autònoma de Barcelona

BACKGROUND

Although it is difficult to ascertain, it is estimated that throughout history have died over **200 million** people because of plague. That is because without an effective treatment, 50–60% of cases of bubonic plague are fatal, while untreated septicaemic and pneumonic plague are **invariably fatal**. [1]

Plague has been used as a weapon many times throughout history, like in 1347 when the Mongols catapulted bodies of infested people into Caffa or during the Second World War when Japan sent rice carrying *Yersinia pestis*.

Yet the most disturbing precedent is the antibiotic-resistant *Yersinia pestis* that the Russians tried to develop. [2]

Nowadays plague can be treated with **streptomycin** or **gentamicin** reducing mortality to only 1-5% of those infected. However, an efficient vaccine that develops protective immune response is lacked. [1][3]

That raises the question of what would happen if these antibiotics didn't work?



Figure 1. *Nicotiana benthamiana* infiltrated with the cultures of *Agrobacterium*




Figure 4. Survival of vaccinated Hartley guinea pigs to aerosolized *Y. pestis* [4].

OBJECTIVES

- Create a subcutaneous vaccine capable of inducing not only humoral but also cellular response.
- Try some different adjuvants and establish which one is the fittest for human vaccination.
- Use viral vectors for expression of recombinant F1 and V proteins in leaves of *N. benthamiana*, to prove that is a rapid, cheap and efficient expression system.
- Develop a vaccine that can protect humankind in case of a terrorist attack with an antibiotic-resistant *Yersinia pestis*.

WORKING PLAN

It has been decided to use a recently developed transfection technology that relies on *Agrobacterium* as an infective systemic agent that delivers deconstructed tobacco mosaic virus (TMV) viral replicons. This improved process is being used to simultaneously start transient gene amplification and high-level expression in all mature leaves of a plant. This technology, combines advantages of three biological systems: vector efficiency and efficient systemic DNA delivery of *Agrobacterium*, speed and expression of a plant RNA virus, as well as low production costs of a plant. [4]





Figure 2. A) Fragments of DNA from Untransformed and Transformed plants B) Southern blot analysis of transgenic lines. Transformed with the integration (9.5kb). And without the integration (8kb) [5].

Adjuvant	B.S.* ₁	1st Shot	B.S.	2nd Shot	B.S.	3rd Shot	B.S.	Trial* ₂
Aluminum Hydroxide	Day 0 Before first dose	Day 0	Day 15	Day 30	Day 45	Day 60	Day 75	Day 90
MF59								
QS-21								
IL-12								
Gram-negative flagellin								
No adjuvant								

Figure 3. Vaccines with the corresponding adjuvant will be administered to 8 guinea pigs each.

*1: Blood sample

*2: Trial with lethal dose 50

EXPECTED RESULTS AND BENEFITS

- It can be expected that the control group will have fewer antibodies in serum and therefore it is also expected a higher rate of deaths.
- It is expected a lower response from Aluminium hydroxide.
- A high level of cellular response with IL-12, QS-21 and MF59 adjuvants.
- Better results than in other studies (fig. 4).
- Determine and optimize the best suited adjuvants for the vaccine.
- Identify flaws in the current system of vaccination
- Provide safety to population in case of a bioterrorist attack.

REFERENCES

- [1] D. T. Dennis, G. L. Campbell. *Harrison Principios de Medicina Interna* (17a edición). Peste y otras infecciones por *Yersinia*. McGraw-Hill Education. 2010. Cap. 152.
- [2] Kristina Hale. *Russian and American use of Yersinia pestis as a Biological Weapon*. [online] 2005.
- [3] J.D. Poland and D. T. Dennis. Plague Manual Epidemiology, Distribution, Surveillance and Control. February 1999. World Health Organization (WHO).
- [4] L. Santi, A. Giritch, C. J. Roy, S. Marillonnet, V. Klimyuk, Y. Gleba, R. Webb, C. J. Arntzen, and H. S. Mason. PNAS. 2006. Vol. 103 no. 4 (861–866)
- [5] P. A. Arlen, M. Singleton, J. J. Adamovicz, Y. Ding, A. Semiromi, H. Daniell. Infection and Immunity. American Society for Microbiology. Aug. 2008. (p. 3640–3650)